Revance and Mylan to Advance Development Program for Biosimilar to BOTOX

Revance Therapeutics Inc and Mylan NV announce Mylan’s decision to move forward with a development plan, under a 351(k) pathway, for a proposed biosimilar to BOTOX and BOTOX Cosmetic (onabotulinumtoxinA), according to a media release.